Expert Interviews

Panelists discuss the supportive care measures Julia considers for patients with advanced EGFR-mutant NSCLC, including interventions like nutrition and exercise, to enhance overall well-being and support treatment outcomes.

Panelists discuss the side effects Melinda has experienced with her current treatment and the strategies she has found most helpful in managing them, while Julia outlines her typical monitoring and follow-up procedures for patients receiving amivantamab, including the frequency of follow-up visits, labs, imaging, and the symptoms or labs that are most concerning during follow-up.

Panelists discuss how bispecifics are sequenced with other B-cell maturation antigen (BCMA)–targeted therapies, such as chimeric antigen receptor (CAR) T cells or antibody drug conjugates (ADCs), and whether early vs late relapse impacts treatment strategies for relapsed/refractory multiple myeloma (R/R MM), with emphasis on how biological and clinical factors influence decision-making.

Panelists discuss the safety and efficacy data from the phase 3 PALOMA-3 trial, and how they may lead to future considerations of the subcutaneous use of amivantamab with lazertinib in the front line.

Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.

Panelists discuss how sacituzumab shows significant efficacy in triple-negative breast cancer, with improved progression-free and overall survival. It demonstrates particular benefit in pretreated patients and brain metastases cases. Trastuzumab deruxtecan (T-DXd) excels in HER2-positive breast cancer treatment, showing remarkable response rates and survival benefits, including in patients with brain metastases and those who progressed on prior therapies.

Panelists discuss how the approach to metastatic disease focuses on systemic therapy, as cancer has spread beyond its primary site. Treatment typically combines targeted therapy, immunotherapy, chemotherapy, and/or hormonal therapy based on cancer type and molecular profile. Goals shift toward extending survival, controlling symptoms, and maintaining quality of life rather than cure. Regular monitoring of treatment response and adverse effects guides ongoing care decisions.

Panelists discusses how triple-negative breast cancer (TNBC) treatment toxicities require careful monitoring and management. Common adverse effects include fatigue, nausea, hair loss, neuropathy from chemotherapy, and radiation-induced skin changes. Health care teams employ preventive strategies, dose modifications, and supportive care to minimize complications while maintaining treatment efficacy.

Panelists discuss how locally advanced triple-negative breast cancer (LATNBC) is an aggressive breast cancer subtype characterized by absence of estrogen receptor, progesterone receptor, and HER2 protein expression. It presents with large tumors and/or extensive lymph node involvement without distant metastasis. Treatment typically involves neoadjuvant chemotherapy followed by surgery and radiation.

Panelists discuss how triple-negative breast cancer (TNBC) is an aggressive form of breast cancer characterized by the absence of 3 key receptors: estrogen receptor, progesterone receptor, and HER2 protein. TNBC tends to grow and spread faster than other breast cancer types, presenting unique treatment challenges since common targeted therapies like hormone therapy and HER2-targeted treatments are ineffective. Standard treatment primarily relies on chemotherapy, surgery, and radiation.

This segment highlights the treatment journey of a 68-year-old IT professional with high-risk multiple myeloma, detailing progression after initial D-RVd therapy, refusal of ASCT, and successful transition to cilta-cel CAR-T therapy with manageable adverse events.

This segment discusses the process and critical importance of bridging strategies for patients awaiting CAR T-cell therapy.

This video episode explores treatment decisions for second-line therapy in a patient with age and comorbidities, reviews cilta-cel data from the CARTITUDE trials, and discusses clinical experience with cilta-cel, emphasizing efficacy, quality of life, and adaptations for complex patient profiles.

This video episode highlights the journey of a 72-year-old retired science teacher with multiple myeloma, covering his treatments, relapse, management of comorbidities, and transition to cilta-cel, supported by his active and healthy wife.

This video segment explores emerging investigational agents for the management of metastatic ALK-positive NSCLC, highlighting promising advancements in the treatment landscape.

This video segment examines therapeutic strategies for managing disease progression on lorlatinib in ALK-positive metastatic NSCLC, including decision-making considerations and scenarios where switching to lorlatinib from another ALK inhibitor may be beneficial.

Panelists discuss how the CheckMate649 study was a randomized trial that compared nivolumab plus FOLFOX (leucovorin, fluorouracil, oxaliplatin) chemotherapy with chemotherapy alone for treating advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The study results found that nivolumab plus chemotherapy improved overall survival and progression-free survival compared with chemotherapy alone.

Panelists discuss how advanced gastric cancer treatments currently include surgery, chemotherapy (primarily platinum/fluoropyrimidine combinations), targeted therapies (trastuzumab for HER2-positive disease, ramucirumab), and immunotherapy (pembrolizumab and nivolumab in select patients). Despite these options, major unmet needs persist, with low survival rates, lack of predictive biomarkers beyond HER2, limited effective treatments after first-line therapy, poor response rates to immunotherapy, and high treatment toxicity affecting quality of life. Many patients also present with late-stage disease due to delayed diagnosis.

Panelists discuss how expanding chimeric antigen receptor (CAR) T-cell therapy into earlier treatment lines for multiple myeloma requires careful consideration of patient selection criteria, treatment sequencing strategies, and infrastructure capacity while awaiting additional clinical evidence.

Panelists discuss how CAR T therapy has transformed the treatment landscape for relapsed/refractory multiple myeloma, highlighting critical factors for success including patient selection, timing of referral, management of adverse effects, and the importance of coordinated care between academic centers and community practices.